Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380149937> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4380149937 endingPage "S24" @default.
- W4380149937 startingPage "S24" @default.
- W4380149937 abstract "To describe real-world outcomes for COVID-19 patients receiving an Early Use Authorization (EUA) treatment (monoclonal antibody [mAb], prophylaxis mAb, antiviral). Administrative claims data from Komodo Health were used to identify US patients (aged ≥12 years) diagnosed with COVID-19 in an ambulatory setting (26 May 2021 and 05 April 2022) and assign to cohorts: (1) Early Treatment: received mAb or antivral for early treatment of COVID-19; (2) Prophylaxis Treatment: received mAb for prophylactic treatment of COVID-19; (3) No Treatment. Index date was defined as the date of treatment or COVID-19 diagnosis date (for the untreated cohort). Patients were continuously enrolled for ≥12 months pre-index and ≥29 days post-index and flagged if meeting the EUA high-risk criteria based on ICD-10 codes and medications received 12-months pre-index. Hospitalization rates and mortality (all-cause for both) within 29 days of index date were described. Of 434,766 patients in the Early Treatment cohort, 80% were high risk, 95% received mAbs (80% high risk), and 5% (86% high risk) received antiviral. The Prophylaxis Cohort comprised 2,015 patients (96% high risk), and the untreated cohort 4,231,748 patients (61% high risk). Differences in baseline characteristics were noted between treated and untreated patients: untreated patients were younger (41 versus 49 years), had a higher proportion of Medicare/Medicaid coverage (32% versus 22%), and lower mean Quan-Charlson score (0.6 versus 0.8). The 29-day hospitalization and/or mortality rate was 3.2% (n=13,707) in Early Treatment (mAb, 3.1%; antiviral, 3.6%), 4.0% (n=80) in Prophylaxis, and 3.6% (n=152,427) in untreated patients (which increased to 4.9% [128,093 of 2,592,568] among high-risk untreated patients). Low rates of adverse clinical outcomes (hospitalization/mortality) were observed during the study period, which included the Delta and early Omicron COVID-19 variants. Differences in patient characteristics warrant careful consideration of designs for future studies. Funding: GSK (Study 218263)" @default.
- W4380149937 created "2023-06-11" @default.
- W4380149937 creator A5014397487 @default.
- W4380149937 creator A5032942541 @default.
- W4380149937 creator A5037677450 @default.
- W4380149937 creator A5042182538 @default.
- W4380149937 creator A5067809504 @default.
- W4380149937 creator A5077494238 @default.
- W4380149937 creator A5091679659 @default.
- W4380149937 date "2023-06-01" @default.
- W4380149937 modified "2023-09-25" @default.
- W4380149937 title "CO56 Real-World Effectiveness of Early Treatments for COVID-19: Evidence from Administrative Claims Data" @default.
- W4380149937 doi "https://doi.org/10.1016/j.jval.2023.03.130" @default.
- W4380149937 hasPublicationYear "2023" @default.
- W4380149937 type Work @default.
- W4380149937 citedByCount "0" @default.
- W4380149937 crossrefType "journal-article" @default.
- W4380149937 hasAuthorship W4380149937A5014397487 @default.
- W4380149937 hasAuthorship W4380149937A5032942541 @default.
- W4380149937 hasAuthorship W4380149937A5037677450 @default.
- W4380149937 hasAuthorship W4380149937A5042182538 @default.
- W4380149937 hasAuthorship W4380149937A5067809504 @default.
- W4380149937 hasAuthorship W4380149937A5077494238 @default.
- W4380149937 hasAuthorship W4380149937A5091679659 @default.
- W4380149937 hasBestOaLocation W43801499371 @default.
- W4380149937 hasConcept C126322002 @default.
- W4380149937 hasConcept C160735492 @default.
- W4380149937 hasConcept C162324750 @default.
- W4380149937 hasConcept C167135981 @default.
- W4380149937 hasConcept C187212893 @default.
- W4380149937 hasConcept C201903717 @default.
- W4380149937 hasConcept C2776534028 @default.
- W4380149937 hasConcept C2779134260 @default.
- W4380149937 hasConcept C3008058167 @default.
- W4380149937 hasConcept C50522688 @default.
- W4380149937 hasConcept C524204448 @default.
- W4380149937 hasConcept C71924100 @default.
- W4380149937 hasConcept C72563966 @default.
- W4380149937 hasConceptScore W4380149937C126322002 @default.
- W4380149937 hasConceptScore W4380149937C160735492 @default.
- W4380149937 hasConceptScore W4380149937C162324750 @default.
- W4380149937 hasConceptScore W4380149937C167135981 @default.
- W4380149937 hasConceptScore W4380149937C187212893 @default.
- W4380149937 hasConceptScore W4380149937C201903717 @default.
- W4380149937 hasConceptScore W4380149937C2776534028 @default.
- W4380149937 hasConceptScore W4380149937C2779134260 @default.
- W4380149937 hasConceptScore W4380149937C3008058167 @default.
- W4380149937 hasConceptScore W4380149937C50522688 @default.
- W4380149937 hasConceptScore W4380149937C524204448 @default.
- W4380149937 hasConceptScore W4380149937C71924100 @default.
- W4380149937 hasConceptScore W4380149937C72563966 @default.
- W4380149937 hasIssue "6" @default.
- W4380149937 hasLocation W43801499371 @default.
- W4380149937 hasLocation W43801499372 @default.
- W4380149937 hasOpenAccess W4380149937 @default.
- W4380149937 hasPrimaryLocation W43801499371 @default.
- W4380149937 hasRelatedWork W1971557041 @default.
- W4380149937 hasRelatedWork W1980275360 @default.
- W4380149937 hasRelatedWork W2157077459 @default.
- W4380149937 hasRelatedWork W2754539770 @default.
- W4380149937 hasRelatedWork W2792210947 @default.
- W4380149937 hasRelatedWork W2912297585 @default.
- W4380149937 hasRelatedWork W2937211356 @default.
- W4380149937 hasRelatedWork W3167110868 @default.
- W4380149937 hasRelatedWork W4312780918 @default.
- W4380149937 hasRelatedWork W2563600304 @default.
- W4380149937 hasVolume "26" @default.
- W4380149937 isParatext "false" @default.
- W4380149937 isRetracted "false" @default.
- W4380149937 workType "article" @default.